Compare WAFD & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | AVDL |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.1B |
| IPO Year | N/A | 1996 |
| Metric | WAFD | AVDL |
|---|---|---|
| Price | $32.88 | $21.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $31.90 | $19.14 |
| AVG Volume (30 Days) | 641.9K | ★ 3.0M |
| Earning Date | 01-15-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.28% | N/A |
| EPS Growth | ★ 29.74 | N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | ★ $734,465,000.00 | $248,517,000.00 |
| Revenue This Year | N/A | $65.47 |
| Revenue Next Year | $4.15 | $30.88 |
| P/E Ratio | $11.42 | ★ N/A |
| Revenue Growth | 3.63 | ★ 79.88 |
| 52 Week Low | $23.75 | $6.38 |
| 52 Week High | $34.30 | $23.57 |
| Indicator | WAFD | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 62.38 |
| Support Level | $32.16 | $21.52 |
| Resistance Level | $33.60 | $21.65 |
| Average True Range (ATR) | 0.62 | 0.07 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 19.55 | 56.00 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.